Innate defense regulator peptide 1018 in wound healing and wound infection

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Steinstraesser, Lars ^a   Hirsch, Tobias ^a   Schulte, Matthias ^a   Kueckelhaus, Maximilian ^a   Jacobsen, Frank ^a   Mersch, Evgenija A ^a   Stricker, Ingo ^a   Afacan, Nicole ^b   Jenssen, Havard ^c   Hancock, Robert E W ^b   Kindrachuk, Jason ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ROSKILDE UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; INNATE DEFENSE REGULATOR PEPTIDE 1018; PEPTIDE HB 107; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; CELL RESPIRATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; SWINE; WOUND CLOSURE; WOUND HEALING; WOUND INFECTION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATHELICIDINS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLONY COUNT, MICROBIAL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KERATINOCYTES; MICE; MICROBIAL SENSITIVITY TESTS; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUS SCROFA; TREATMENT OUTCOME; WOUND HEALING; WOUND INFECTION;

BACTERIA (MICROORGANISMS); MURINAE; STAPHYLOCOCCUS AUREUS; SUS;

EID: 84864717609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039373     Document Type: Article

References (38)

1. Singer AJ, Clark RA, ((1999)) Cutaneous wound healing. N Engl J Med 341:738-746.
2. Hirsch T, Jacobsen F, Steinau HU, Steinstraesser L, ((2008)) Host defense peptides and the new line of defence against multiresistant infections. Protein Pept Lett 15:238-243.
3. Steinstraesser L, Kraneburg UM, Hirsch T, Kesting M, Steinau HU, et al. ((2009)) Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int J Mol Sci 10:3951-3970.
4. Steinstraesser L, Oezdogan Y, Wang SC, Steinau HU, ((2004)) Host defense peptides in burns. Burns 30:619-627.
5. Hirsch T, Spielmann M, Zuhaili B, Fossum M, Metzig M, et al. ((2009)) Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Gene Med 11:220-228.
6. Otte JM, Zdebik AE, Brand S, Chromik AM, Strauss S, et al. ((2009)) Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept 156:104-117.
7. Steinstraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O, et al. ((2008)) Host defense peptides in wound healing. Mol Med 14:528-537.
8. Steinstraesser L, Ring A, Bals R, Steinau HU, Langer S, ((2006)) The human host defense peptide LL37/hCAP accelerates angiogenesis in PEGT/PBT biopolymers. Ann Plast Surg 56:93-98.
9. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, et al. ((2000)) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192:1069-1074.
10. Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, et al. ((2002)) A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106:20-26.
11. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, et al. ((2005)) Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 174:4271-4278.
12. Elssner A, Duncan M, Gavrilin M, Wewers MD, ((2004)) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172:4987-4994.
13. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW, ((2002)) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169:3883-3891.
14. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, et al. ((2003)) The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 171:6690-6696.
15. Li J, Post M, Volk R, Gao Y, Li M, et al. ((2000)) PR39, a peptide regulator of angiogenesis. Nat Med 6:49-55.
16. Oono T, Shirafuji Y, Huh WK, Akiyama H, Iwatsuki K, ((2002)) Effects of human neutrophil peptide-1 on the expression of interstitial collagenase and type I collagen in human dermal fibroblasts. Arch Dermatol Res 294:185-189.
17. Shi J, Ross CR, Leto TL, Blecha F, ((1996)) PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc Natl Acad Sci U S A 93:6014-6018.
18. Gallo RL, Ono M, Povsic T, Page C, Eriksson E, et al. ((1994)) Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A 91:11035-11039.
19. Hancock REW, Sahl HG, ((2006)) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551-1557.
20. Zhang L, Falla TJ, ((2009)) Host defense peptides for use as potential therapeutics. Curr Opin Investig Drugs 10:164-171.
21. Lee PH, Rudisill JA, Lin KH, Zhang L, Harris SM, et al. ((2004)) HB-107, a nonbacteriostatic fragment of the antimicrobial peptide cecropin B, accelerates murine wound repair. Wound Repair Regen 12:351-358.
22. Easton DM, Nijnik A, Mayer ML, Hancock RE, ((2009)) Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol 27:582-590.
23. Lee HY, Bae YS, ((2008)) The anti-infective peptide, innate defense-regulator peptide, stimulates neutrophil chemotaxis via a formyl peptide receptor. Biochem Biophys Res Commun 369:573-578.
24. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, et al. ((2010)) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184:2539-2550.
25. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, et al. ((2007)) An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 25:465-472.
26. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, et al. ((2005)) Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77:451-459.
27. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, et al. ((1997)) Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560.
28. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B, ((1998)) Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273:3718-3724.
29. Wieczorek M, Jenssen H, Kindrachuk J, Scott WR, Elliott M, et al. ((2010)) Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol 17:970-980.
30. Carretero M, Escamez MJ, Garcia M, Duarte B, Holguin A, et al. ((2008)) In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 128:223-236.
31. Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, et al. ((2001)) Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117:91-97.
32. Gallo RL, Murakami M, Ohtake T, Zaiou M, ((2002)) Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 110:823-831.
33. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, et al. ((2003)) The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 120:379-389.
34. Steiner H, Hultmark D, Engstrom A, Bennich H, Boman HG, ((1981)) Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292:246-248.
35. Brem H, Tomic-Canic M, ((2007)) Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117:1219-1222.
36. Coleman DL, ((1982)) Diabetes-obesity syndromes in mice. Diabetes 31:1-6.
37. Fusenig NE, Boukamp P, ((1998)) Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 23:144-158.
38. Jacobsen F, Baraniskin A, Mertens J, Mittler D, Mohammadi-Tabrisi A, et al. ((2005)) Activity of histone H1.2 in infected burn wounds. J Antimicrob Chemother 55:735-741.